AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05229276 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bone Wax
Description: patients in this group were given Bone Wax as the hemostatic material during sternotomy. Midline sternotomy with an oscillating saw was conducted after standard aseptic surgical techniques. Bone wax was applied to both spongiosa surfaces of resected sternal bones until bleeding had ceased.
Study NCT04601753 — intervention group
Intervention type: DRUG
Intervention: Oral Semaglutide
Description: Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
Study NCT00943839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Study NCT00943839 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT00943839 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study NCT02837224 — intervention group
Intervention type: DEVICE
Intervention: The Situate Detection System
Description: The Situate Detection System for locating surgical sponges
Study NCT01716897 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: E2609
Study NCT04361955 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: EMG
Description: recordings of muscle electrical activity during nerve stimulation using EMG
Study NCT01685879 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Glucose Beverage
Description: Glucose beverage that provides 50 g total carbohydrate.
Study NCT03194477 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile-enhanced Engagement Intervention
Description: Mobile phone based enhanced case management intervention for HIV positive \& HIV negative young Black men who have sex with men.
Study NCT04361955 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: EEG
Description: recordings of brain activity using EEG
Study NCT06245148 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Observation
Study NCT00770029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (Xeomin) (20 Units)
Description: The treatment will be administered only once at day 0 at five injection sites in the glabellar area. The total dose of 20 Units IncobotulinumtoxinA (Xeomin) is reconstituted in a total injection volume of 0.5 mL that is to be injected to the five sites in equal aliquots of 0.1 mL.
Study NCT00706316 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBV-Specific CTLs and CD45 Mab
Description: One time infusion (IV) at one of the following dose levels:~Dose level I: 5 x 107 cells/m2~Dose level II: 1 x 108 cells/m2~Dose level III: 2 x 108 cells/m2
Study NCT01558934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lofexidine HCl
Description: Lofexidine HCl 0.2 mg tablets titrated in ascending doses of 0.2 mg QID (e.g. Day 1 0.2 mg QID, Day 2 0.4 QID, etc)as described in the treatment arm.
Study NCT02841124 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: interviews
Description: face-to-face interviews with the referent oncologist (or hematologist) and his patient (conducted by a physician and a psychologist respectively) as well as interviews with other partners involved in the situation (care staff and relatives)
Study NCT00770029 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The treatment will be administered only once at day 0 at five injection sites in the glabellar area. Volume of Placebo equivalent to IncobotulinumtoxinA (Xeomin).
Study NCT04945889 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quick Sequential Organ Failure Assessment (qSOFA)
Description: Clinical bedside tool that evaluates three vital parameters, scoring one point each if altered: respiratory rate (RR) ≥22 breaths/minute, systolic blood pressure (SBP) ≤100 mmHg and altered mental status (defined in our study as either Glasgow Coma Scale (GCS) score \<15 or any worsening in the Italian Oriented, Disoriented, Agitated, Sleepy scale). A qSOFA score ≥2 points is considered indicative of sepsis.
Study NCT04945889 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Modified Early Warning Score (MEWS)
Description: Clinical bedside tool that evaluates five vital parameters, with multiple scoring according to alteration: respiratory rate (0-3 points), heart rate (0-3 points), systolic blood pressure (0-3 points), body temperature (0-2 points), mental status (0-3 points, evaluated using the Alert, Verbal, Pain, Unresponsive - AVPU scale). A MEWS score ≥5 points is considered indicative of an acute condition at risk of sudden clinical deterioration.
Study NCT04945889 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: National Early Warning Score (NEWS)
Description: Clinical bedside tool that evaluates seven parameters, with multiple scoring according to alteration: respiratory rate (0-3 points), oxygen saturation (0-3 points), need for any supplemental oxygen (0-2 points), body temperature (0-3 points), heart rate (0-3 points), systolic blood pressure (0-3 points), mental status (0-3 points, evaluated using the Alert, Verbal, Pain, Unresponsive - AVPU scale). A NEWS score ≥7 points is considered indicative of an acute condition at risk of sudden clinical deterioration.
Study NCT02121951 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local Anesthetic infiltration
Description: Lignocaine infiltration through the nephrostomy track
Study NCT02121951 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum block
Description: A linear 12-MHz ultrasound probe will be placed in the anterior axillary line to visualize the typical triple abdominal layers. Then, the probe will be placed in the midaxillary line and at this point the layers of abdominal layers starte to taper. The probe will be placed in the posterior axillary line, sonoanatomy will show first the transversus abdominis disappearing then the internal oblique and external oblique forming aponeurosis and appearance of QL will be noticed. At the posterior border of the quadratus lumborum muscle and outside the fascia, Touhe needle will be inserted in plane and confirmed its position by injecting saline. Under ultrasound (US) guidance, local anesthetic mixure will be deposited separating the fascia
Study NCT02121951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MAC
Description: Incremental doses are given to the targed sedation and analgesia
Study NCT02121951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAC
Description: Incremental doses are given to the targed sedation and analgesia
Study NCT02746432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyper insulinemic euglycemic clamp
Description: After obtaining a baseline preoperative lab set blood glucose value, 2 U/kg bolus of insulin (Human regular insulin) to be administered IV followed by an infusion of 2 U/ kg/min.fiver - Ten minutes after starting the insulin infusion, and when the blood glucose is \<6.1 mmol /L (110 mg /dL). an Infusion of dextrose 20% supplemented with pottasium phosphate (30 mmol/L ) to be administered. In the operating room, blood glucose levels were measured every 5-15 minutes, and the dextrose infusion rate was adjusted to maintain arterial glycemia between 3.5 and 6.1 mmol/L (63-110 mg/dL). timed intra operative lab assessment to be obtained.
Study NCT00818168 — intervention group
Intervention type: BIOLOGICAL
Intervention: Infliximab
Description: Dosage and infusion intervals were employed in~accordance to the Summary of Product Characteristics (SmPC)
Study NCT00535756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creon
Description: 3 capsules Creon with 25000 lipase units per main meal (3 main meals) plus 2 capsules per snack (2-3 snacks)
Study NCT00535756 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04094688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT04094688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Given IV
Study NCT04094688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study NCT04094688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Given IV
Study NCT04094688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT04094688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT04094688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT04094688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Given IV
Study NCT04094688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV
Study NCT04094688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan Hydrochloride
Description: Given IV
Study NCT04094688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV
Study NCT04094688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Given IV
Study NCT04094688 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Given PO
Study NCT04094688 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Given PO
Study NCT04094688 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04094688 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04094688 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04094688 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03745911 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Paclitaxel and TAK-228
Description: Treatment with TAK-228 oral (D2, 3 and 4 of each week) and paclitaxel (D1 of each week) on Days 1, 8 and 15 for each 28-days cycle until disease progression or unacceptable toxicity. If paclitaxel is stopped, TAK-228 may be continued
Study NCT02914418 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation using iTBS Paradigm
Description: TMS is a non-invasive, painless method of stimulating the central and peripheral nervous system. ITBS is a form of TMS which is delivered for \~200sec and can promote changes in neural activity.
Study NCT02914418 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation using iTBS Paradigm
Description: TMS is a non-invasive, painless method of stimulating the central and peripheral nervous system. ITBS is a form of TMS which is delivered for \~200sec and can promote changes in neural activity.
Study NCT02365727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Study NCT02365727 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liposomal bupivacaine
Study NCT02365727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Study NCT02365727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Study NCT02365727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Study NCT02365727 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT03988244 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeartLight X3
Description: Pulmonary vein isolation
Study NCT03635528 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 1
Description: EMO-114
Study NCT03635528 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 2
Description: EMO-116
Study NCT01584713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adipose-derived stem cells without expanded
Description: Administration will be intralesional injection of cells suspension. They will be placed into fistula walls
Study NCT02969785 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: G1: exercises for lumbar stabilization
Description: Specific exercises for lumbar stabilization. The Group 1 (G1) will perform therapy with specific exercises for lumbar stabilization whith the Swiss ball as a therapeutic resource, including warming; stretching of hamstrings, paraspinals, trapezes; phasic perineal exercise; tonic perineal exercise; pelvic lumbar synergism; trunk mobility; mobility of the shoulder girdle; balance; and slow pelvic balance.
Study NCT02969785 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: G2: back strengthening exercises
Description: Specific back exercises. The Group 2 (G2) will perform therapy including back strengthing exercise on a Roman chair machine to perform flexion and extension of trunk with load progressive training.
Study NCT02810782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenobarbital
Description: Phenobarbital per os
Study NCT02810782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorpromazine
Description: Chlorpromazine per os
Study NCT02810782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine per os
Study NCT02989974 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KY LEADS Survivorship Care
Description: Survivor: Survivor questionnaire 1 at enrollment; KY LEADS Survivorship Care Program; survivor questionnaire 2 one week after program completion; survivor questionnaire 3 six months after enrollment.~Caregiver: Caregiver questionnaire 1 at enrollment;KY LEADS Survivorship Care Program; caregiver questionnaire 2 one week after program completion; caregiver questionnaire 3 six months after enrollment
Study NCT00598091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Description: 1000mg/m2, Days 1, 8, 15
Study NCT00598091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dasatinib
Description: 50mg, PO, QD
Study NCT00598091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Description: 1000mg/m2, days 1, 8, 15
Study NCT00598091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dasatinib
Description: 50mg, PO, BID
Study NCT03635528 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 3
Description: EMO-118
Study NCT01963871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Twice weekly one hour sessions of Hatha Yoga for 12 weeks
Study NCT01776086 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neurological testing
Study NCT02247388 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Alcohol Screening
Description: iPad based automated alcohol screening
Study NCT02247388 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Negotiated Interview
Description: iPad based automated brief negotiated interview (BNI)
Study NCT03659630 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyCompass
Description: Self-help tools to change behaviours in various different domains including sleep deprivation, anxiety and depression.
Study NCT03659630 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparison group
Description: An email containing a brief text on general tips regarding mental health was sent out once a week.
Study NCT03863353 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: This intervention provides scenario-tailored opioid risk message feedback immediately following interactive analgesic decision-making exercises.
Study NCT01330082 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adjunctive Photodynamic Therapy
Description: using Light-emitting diod(LED) (625-635nm,200mw/cm2 ,30 s for each site, fotoson CMS Dental ,Denmark) in the presence of toluidine blue O (TBO)
Study NCT01330082 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Light-emitting diod Irradiation
Description: 625-635nm,200mw/cm2 ,30 s for each site, fotoson CMS Dental ,Denmark
Study NCT01330082 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: applying Photosensitizer
Description: toluidine blue O is applied at the bottom of each periodontal pocket
Study NCT02108301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus-cyclosporine A
Description: conversion of immunosuppression from tacrolimus to cyclosporine A in hepatitis C-positive renal transplant recipients
Study NCT03171090 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sphenopalatine block with local anesthetic
Description: bilateral ultrasonic guided sphenopalatine ganglion block using local anesthetic after induction of general anesthesia in maxilofacial cancer surgeries
Study NCT03171090 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sphenopalatine block with saline
Description: bilateral ultrasonic guided sphenopalatine ganglion block using saline after induction of general anesthesia in maxilofacial cancer surgeries
Study NCT00167700 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary counselling and placebo
Description: Counseling to conform with the dietary recommendations. Food products commercially available including spreads and salad dressing. Placebo capsules.
Study NCT00167700 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary counselling and probiotics
Description: Counseling to conform with the dietary recommendations. Food products commercially available including spreads and salad dressing. Probiotics
Study NCT00167700 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Placebo capsules
Study NCT00167700 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Study NCT00167700 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotics
Study NCT00595361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salmeterol
Description: salmeterol 50 micrograms twice daily for 2 weeks
Study NCT05647187 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Serum Interleukin 17 levels
Description: Serum Interleukin 17 levels will be measured pre and post treatment by NB-UVB by performing an enzyme-linked immune sorbent assay (ELISA)
Study NCT05647187 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: NB-UVB
Description: patients will be exposed to narrow band UVB twice weekly for three months
Study NCT02779985 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lycium Barbarum mixed meal
Description: This mixed meal contains 25 grams of dried Lycium Barbarum (Goji berry, Wolfberry)
Study NCT02779985 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control mixed meal
Description: This mixed meal does not contain Lycium Barbarum, but is matched for energy and macronutrient content
Study NCT04079790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gepotidacin
Description: Tablets containing gepotidacin mesylate with a unit dose of 750 mg will be administered orally with 240 milliliter (mL) of water.
Study NCT04079790 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets containing unit dose of placebo matching of gepotidacin will be administered orally with 240 mL of water.
Study NCT03434288 — intervention group
Intervention type: OTHER
Intervention: Bone sampling
Description: Bone biopsy in Diabetic patients with foot osteomyelitis
Study NCT04351620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Tolerability study of HCQ 1200 mg administered daily in divided doses for a duration of 5-10 days
Study NCT02618746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Study NCT02618746 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hospital based Rehabilitation
Study NCT02136693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psyllium fiber
Description: 3.5 g /day of pure Psyllium fiber for 180 days after STARR
Study NCT02136693 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3.5 g /day of inert compound for 180 days after STARR
Study NCT01482559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dopamine hydrochloride
Description: Active drug substance 1.5 mg in 1 mL IV Infusion Minimum dose = 5mcg/kg/min Maximum dose = 20mcg/kg/min
Study NCT01482559 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose 5%
Description: IV Infusion Minimum dose = 5mcg/kg/min Maximum dose = 20mcg/kg/min
Study NCT02064556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 10mg
Description: Amlodipine 10mg 1T, PO, QD for 9days
Study NCT02064556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 10mg/Candesartan 32mg
Description: Amlodipine 10mg 1T, PO, QD for 9days/Candesartan 32mg 1T, PO, QD for 9days